[1] |
Ni Q, Chen X, Zhang P, et al. Systematic estimation of cystic fibrosis prevalence in Chinese and genetic spectrum comparison to Caucasians[J]. Orphanet J Rare Dis, 2022, 17(1): 129. DOI: 10.1186/s13023-022-02279-9.
|
[2] |
郭小贝,田欣伦. 囊性纤维化[M]//张抒扬. 中国第一批罕见病目录释义.北京:人民卫生出版社,2018:315-317.
|
[3] |
Sun J, Hua L, He Y, et al.Genetic analysis and functional study of novel CFTR variants in Chinese children with cystic fibrosis[J]. Gene, 2024, 907: 148190. DOI: 10.1016/j.gene.2024.148190.
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
Shen Y, Tang X, Chen Q, et al. Genetic spectrum of Chinese children with cystic fibrosis: comprehensive data analysis from the main referral centre in China[J]. J Med Genet, 2022, 60(3): 310-315. DOI: 10.1136/jmg-2022-108501.
|
[12] |
Liu K, Xu W, Xiao M,et al. Characterization of clinical and genetic spectrum of Chinese patients with cystic fibrosis[J]. Orphanet J Rare Dis, 2020, 15(1): 150. DOI: 10.1186/s13023-020-01393-w.
|
[13] |
Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective[J]. Lancet Respir Med, 2020, 8(1): 65-124.DOI: 10.1016/S2213-2600(19)30337-6.
|
[14] |
Helbich TH, Heinzpeer G, Eichler I, et al. Cystic fibrosis: CT assessment of lung involvement in children and adults[J]. Radiology, 1999, 213(2): 537-544. DOI: 10.1148/radiology.213.2.r99nv04537.
|
[15] |
|
[16] |
|
[17] |
Gillespie CD, O′Reilly MK, Allen GN,et al. Imaging the abdominal manifestations of cystic fibrosis[J]. Int J Hepatol, 2017: 512-760. DOI: 10.1155/2017/5128760.
|
[18] |
Baker RD. Assessing exocrine pancreatic function: when the best test is not possible[J]. J Pediatr Gastroenterol Nutr, 2013, 56(2): 116-117.DOI: 10.1097/MPG.0b013e31827e2293.
|
[19] |
Guo X, Liu K, Liu Y, et al. Clinical and genetic characteristics of cystic fibrosis in Chinese patients: a systemic review of reported cases[J]. Orphanet J Rare Dis, 2018, 13(1): 224. DOI: 10.1186/s13023-018-0968-2.
|
[20] |
Bienvenu T, Lopez M, Girodon E. Molecular diagnosis and genetic counseling of cystic fibrosis and related disorders: new challenges[J]. Genes (Basel), 2020, 11(6): 619. DOI: 10.3390/genes11060619.
|
[21] |
Wielpütz MO, Eichinger M, Biederer J,et al. Imaging of cystic fibrosis lung disease and clinical interpretation[J]. Rofo, 2016, 188(9): 834-845.DOI: 10.1055/s-0042-104936.
|
[22] |
Tepper LA, Caudri D, Rovira AP, et al. The development of bronchiectasis on chest computed tomography in children with cystic fibrosis: can pre-stages be identified[J]. Eur Radiol, 2016, 26(12): 4563-4569. DOI: 10.1007/s00330-016-4329-z.
|
[23] |
Abdul Aziz D, Siddiqui F, Abbasi Q, et al. Characteristics of electrolyte imbalance and pseudo-Bartter syndrome in hospitalized cystic fibrosis children and adolescents[J]. J Cyst Fibros, 2022, 21(3): 514-518.DOI: 10.1016/j.jcf.2021.09.013.
|
[24] |
Martiniao SL, Toprak D, Ong T, et al. Highlights from the 2017 North American cystic fibrosis conference[J]. Pediatr Pulmonol, 2018, 53(7): 979-986. DOI: 10.1002/ppul.24000.
|
[25] |
Taylor-Cousar JL, Munck A, Mckone EF, et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del[J]. N Engl J Med, 2017, 377(21):2013-2023.DOI: 10.1056/NEJMoa1709846.
|
[26] |
Keating D, Marigowda G, Burr L, et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two phe508del alleles[J]. N Engl J Med, 2018, 379(17): 1612-1620. DOI: 10.1056/NEJMoa1807120.
|
[27] |
|
[28] |
Griese M, Costa S, Linnemenn RW, et al. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an openlabel phase 3 clinical trial[J]. Am J Respir Crit Care Med, 2021, 203(3): 381-385. DOI: 10.1164/rccm.202008-3176LE.
|
[29] |
|